Weight Loss Pills vs Injections: Which Approach Actually Works Better?

Step 1: Understand what each licensed option actually is

There are currently three licensed GLP-1 weight-management medicines available through private prescription in the UK. Mounjaro (tirzepatide) and Wegovy (semaglutide) are once-weekly subcutaneous injections delivered via pre-filled pens. The Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK, is a once-daily semaglutide tablet taken first thing in the morning on an empty stomach with a small amount of plain water, at least 30 minutes before food or other medicines.

Mounjaro is a dual GIP and GLP-1 receptor agonist, making it the only medicine in this class that activates two gut-hormone receptors. Both Wegovy formats activate GLP-1 receptors only. All three slow gastric emptying and reduce appetite; the injection routes avoid the absorption challenge that oral semaglutide has to overcome with its SNAC co-formulation. The weight-loss injection options and the tablet option are not interchangeable, and the prescriber, not the patient, decides which is clinically appropriate.

Ozempic (also semaglutide) and Rybelsus (oral semaglutide at lower doses) are licensed for type 2 diabetes, not weight management. They are not options for weight-loss treatment and should not be sought for that purpose.

Step 2: Compare the trial evidence side by side

The table below sets out the headline figures from the phase-3 trials that underpinned UK licensing. These are population averages from controlled studies; individual results will differ.

In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced a greater average weight reduction than semaglutide 2.4mg over 72 weeks. The Wegovy 7.2mg single-dose pen, approved by the MHRA in April 2026, reported approximately 20.7% average weight loss in its trial programme, narrowing the gap considerably. For the tablet, the 17% figure applies specifically to participants who stayed fully adherent in the OASIS 4 trial and should not be read as the general expected outcome.

If you want to dig into how the injection options compare with each other in more depth, the head-to-head injection comparison covers the SURMOUNT-5 data in detail.

Step 3: Weigh the practical differences that affect real-world use

For many people, the question of whether injections are better than pills for weight loss comes down to day-to-day reality rather than trial percentages. The injection pens require refrigeration at 2–8°C and involve a once-weekly subcutaneous injection. Some people find a weekly routine easier to sustain; others are put off by needles or storage logistics. The Wegovy tablet needs no refrigeration, which makes it straightforwardly travel-friendly and removes the fridge dependency entirely. The trade-off is a strict morning routine: swallow the tablet before anything else, including coffee, and wait at least half an hour before eating or taking other oral medicines.

The gastrointestinal side-effect profile is similar across the class: nausea, vomiting, diarrhoea and constipation are the most common, particularly after starting or moving up a dose. In the OASIS 4 trial, 74% of tablet users reported GI effects versus 42% in the placebo group; most were mild to moderate and settled over time. If you are weighing up whether weight loss injections are better than tablets, it is worth knowing that the injection format showed comparable GI patterns in SURMOUNT and STEP trials. Neither format is side-effect-free, and the prescriber takes your full medical history into account when recommending one over the other.

The injection pens require a sharps disposal bin at home. If you start on an injection and want to know about disposal, a 1-litre sharps container is available from our pharmacy. For a broader look at the cost context across formats, our weight-loss injection pricing page sets out what private treatment typically covers.

Step 4: Let the prescriber map the evidence to your situation

NICE recommends tirzepatide (TA1026) for adults with a BMI of 35 or above alongside at least one weight-related condition; lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE's recommendation for the Wegovy injection (TA875) applies within specialist weight management services for up to two years. The oral Wegovy tablet is not yet appraised by NICE and is available on private prescription only. If you are still deciding between formats, our guide to weight loss pills vs injections walks through the key considerations before you speak to a prescriber. Across all three options, a prescriber assesses eligibility on the full clinical picture, not BMI alone.

A clinician who has reviewed your health summary will give you a clearer steer than any comparison table. Our prescribers at nume review every consultation personally on the same day. Details of our clinical team's approach are on the clinical team page. For a broader overview of all available treatment routes, the weight management treatment overview is a practical starting point. Which option suits you is a clinical decision our prescribers make with you, based on your health, preferences and goals.